The number of CD25+tumor-infiltrating cells may predict clinical response to rituximab in follicular lymphoma patients. 46th Annual Meeting of the American-Society-of-Hematology Park, C. Y., Bohen, S. P., Levy, R., Warnke, R. A., Natkunam, Y. AMER SOC HEMATOLOGY. 2004: 214A–214A

View details for Web of Science ID 000225127500750